Search

Your search keyword '"Giancola, M. L."' showing total 33 results
Start Over Author "Giancola, M. L."
33 results on '"Giancola, M. L."'

2. Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia

Author

Vergori, A., Lorenzini, P., Cozzi-Lepri, A., Donno, D. R., Gualano, G., Nicastri, E., Iacomi, F., Marchioni, L., Campioni, P., Schinina, V., Cicalini, S., Agrati, C., Capobianchi, M. R., Girardi, E., Ippolito, G., Vaia, F., Petrosillo, N., Antinori, A., Taglietti, F., The ReCOVeRI Study Group: Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Castilletti, C., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Corpolongo, A., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., D'Offizi, G., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Fusto, M., Galati, V., Gagliardini, R., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Iaconi, M., Iannicelli, G., Inversi, C., Lalle, E., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Loiacono, L., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Mondi, A., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palmieri, F., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Valli, M. B., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., Zanetti, A., Zito, S., Vergori, A., Lorenzini, P., Cozzi-Lepri, A., Donno, D. R., Gualano, G., Nicastri, E., Iacomi, F., Marchioni, L., Campioni, P., Schinina, V., Cicalini, S., Agrati, C., Capobianchi, M. R., Girardi, E., Ippolito, G., Vaia, F., Petrosillo, N., Antinori, A., Taglietti, F., Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Castilletti, C., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Corpolongo, A., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., D'Offizi, G., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Fusto, M., Galati, V., Gagliardini, R., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Iaconi, M., Iannicelli, G., Inversi, C., Lalle, E., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Loiacono, L., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Mondi, A., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palmieri, F., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Valli, M. B., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., Zanetti, A., and Zito, S.

Subjects
Male, medicine.medical_treatment, Rome, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Severity of Illness Index, 0302 clinical medicine, Retrospective Studie, Coagulopathy, Clinical endpoint, Intubation, Respiratory function, 030212 general & internal medicine, Multidisciplinary, Middle Aged, Medicine, Female, Human, medicine.medical_specialty, Patients, medicine.drug_class, Science, Low molecular weight heparin, Risk Assessment, Article, NO, 03 medical and health sciences, Internal medicine, Severity of illness, medicine, Intubation, Intratracheal, Humans, Retrospective Studies, Aged, business.industry, SARS-CoV-2, COVID-19, Thrombocytopenia, Retrospective cohort study, Heparin, Low-Molecular-Weight, medicine.disease, Respiration, Artificial, COVID-19 Drug Treatment, respiratory tract diseases, Pneumonia, Viral infection, business
Abstract

Prophylactic low molecular weight heparin (pLMWH) is currently recommended in COVID-19 to reduce the risk of coagulopathy. The aim of this study was to evaluate whether the antinflammatory effects of pLMWH could translate in lower rate of clinical progression in patients with COVID-19 pneumonia. Patients admitted to a COVID-hospital in Rome with SARS-CoV-2 infection and mild/moderate pneumonia were retrospectively evaluated. The primary endpoint was the time from hospital admission to orotracheal intubation/death (OTI/death). A total of 449 patients were included: 39% female, median age 63 (IQR, 50–77) years. The estimated probability of OTI/death for patients receiving pLMWH was: 9.5% (95% CI 3.2–26.4) by day 20 in those not receiving pLMWH vs. 10.4% (6.7–15.9) in those exposed to pLMWH; p-value = 0.144. This risk associated with the use of pLMWH appeared to vary by PaO2/FiO2 ratio: aHR 1.40 (95% CI 0.51–3.79) for patients with an admission PaO2/FiO2 ≤ 300 mmHg and 0.27 (0.03–2.18) for those with PaO2/FiO2 > 300 mmHg; p-value at interaction test 0.16. pLMWH does not seem to reduce the risk of OTI/death mild/moderate COVID-19 pneumonia, especially when respiratory function had already significantly deteriorated. Data from clinical trials comparing the effect of prophylactic vs. therapeutic dosage of LMWH at various stages of COVID-19 disease are needed.

Published
2021

3. SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection

Author

Colavita F., Lapa D., Carletti F., Lalle E., Bordi L., Marsella P., Nicastri E., Bevilacqua N., Giancola M. L., Corpolongo A., Ippolito G., Capobianchi M. R., Castilletti C., Abbonizio M. A., Agrati C., Albarello F., Amadei G., Amendola A., Antonini M., Barbaro R., Bartolini B., Benigni M., Bordoni V., Branca M., Campioni P., Caporale C., Caravella I., Chiappini R., Ciaralli C., Cristofaro M., Curiale S., D'Abramo A., Dantimi C., de Angelis A., de Angelis G., Di Lorenzo R., Di Stefano F., Ferraro F., Fiorentini L., Frustaci A., Galli P., Garotto G., Giansante F., Giombini E., Greci M. C., Lanini S., Lepore L., Lucia A., Lufrani F., Macchione M., Marani A., Marchioni L., Mariano A., Marini M. C., Maritti M., Matusali G., Meschi S., Messina F., Montaldo C., Murachelli S., Noto R., Palazzolo C., Pallini E., Passeri V., Pelliccioni F., Petrecchia A., Petrone A., Petrosillo N., Pianura E., Pisciotta M., Pittalis S., Proietti C., Puro V., Rinonapoli G., Rueca M., Sacchi A., Sanasi F., Santagata C., Scarcia S., Schinina V., Scognamiglio P., Scorzolini L., Stazi G., Vaia F., Vairo F., Valli M. B., Colavita, F., Lapa, D., Carletti, F., Lalle, E., Bordi, L., Marsella, P., Nicastri, E., Bevilacqua, N., Giancola, M. L., Corpolongo, A., Ippolito, G., Capobianchi, M. R., Castilletti, C., Abbonizio, M. A., Agrati, C., Albarello, F., Amadei, G., Amendola, A., Antonini, M., Barbaro, R., Bartolini, B., Benigni, M., Bordoni, V., Branca, M., Campioni, P., Caporale, C., Caravella, I., Chiappini, R., Ciaralli, C., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., de Angelis, A., de Angelis, G., Di Lorenzo, R., Di Stefano, F., Ferraro, F., Fiorentini, L., Frustaci, A., Galli, P., Garotto, G., Giansante, F., Giombini, E., Greci, M. C., Lanini, S., Lepore, L., Lucia, A., Lufrani, F., Macchione, M., Marani, A., Marchioni, L., Mariano, A., Marini, M. C., Maritti, M., Matusali, G., Meschi, S., Messina, F., Montaldo, C., Murachelli, S., Noto, R., Palazzolo, C., Pallini, E., Passeri, V., Pelliccioni, F., Petrecchia, A., Petrone, A., Petrosillo, N., Pianura, E., Pisciotta, M., Pittalis, S., Proietti, C., Puro, V., Rinonapoli, G., Rueca, M., Sacchi, A., Sanasi, F., Santagata, C., Scarcia, S., Schinina, V., Scognamiglio, P., Scorzolini, L., Stazi, G., Vaia, F., Vairo, F., and Valli, M. B.

Subjects
Isolation (health care), Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Eye, NO, 03 medical and health sciences, 0302 clinical medicine, Internal Medicine, Medicine, Viral rna, 030304 developmental biology, 0303 health sciences, SARS-CoV-2, business.industry, COVID-19, RNA, Pneumonia, General Medicine, Conjunctivitis, medicine.disease, Letters: Observations, Virology, 3. Good health, Viral replication, 030221 ophthalmology & optometry, business, Viral load, COVID-19, Conjunctivitis, Eye, Pneumonia, SARS-CoV-2
Abstract

Background: Coronavirus disease 2019 (COVID-19), the disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in China in December 2019, was recently recognized as pandemic threat by the World Health Organization, with the potential of rapidly overloading health care systems and causing substantial mortality worldwide (www.who.int/dg/speeches/detail/who-director-general -s-opening-remarks-at-the-media-briefing-on-covid-19 —11-march -2020). Human-to-human transmission occurs mainly through respiratory droplets, but other routes are under investigation, because SARS-CoV-2 has been detected in several body fluids (1). So far, few data are available on ocular samples from patients with COVID-19, although conjunctivitis has been occasionally reported among COVID-19 symptoms, similar to infections caused by other human coronaviruses (2, 3). During the SARS epidemic, eye exposure to infectious fluids was associated with an increased risk for SARS-CoV transmission to health care workers (3, 4). Although SARS-CoV RNA was occasionally found in ocular specimens during the early phase of illness, its infectivity is unknown (2, 3). With regard to COVID-19, unprotected ocular exposure was thought to be responsible for infections that occurred in the Wuhan Fever Clinic in January 2020 (3, 4); in addition, SARS-CoV-2 RNA was detected in conjunctival secretions collected from the only patient with conjunctivitis out of 30 patients with COVID-19 from a hospital in China (5). However, further studies are needed to evaluate the infectious potential of the SARS-CoV-2 RNA detected in the ocular specimens and to determine whether transmission may occur through ocular secretions (3, 4). Objective: To present the early detection of infectious SARS-CoV-2 in ocular fluids from a patient with the first confirmed case of COVID-19 in Italy, who had been hospitalized at the National Institute for Infectious Diseases “L. Spallanzani” (INMI) in Rome. Methods and Findings: The patient, a 65-year-old woman, travelled from Wuhan, China, to Italy on 23 January 2020 and was admitted on 29 January 2020, 1 day after symptom onset. At admission to the high isolation unit at INMI, she presented with nonproductive cough, sore throat, coryza, and bilateral conjunctivitis. She had no fever until day 4, when fever (38 °C), nausea, and vomiting began. Infection with SARS-CoV-2 was confirmed by performing real-time reverse transcription polymerase chain reaction (RT-PCR) assay on sputum samples (cycle threshold value [Ct], 16.1) on the admission day, followed by viral M gene sequencing (GenBank accession number MT008022), and virus isolation on Vero E6 cell line (2019-nCoV/Italy-INMI1). The full genome sequence was obtained from either clinical sample or culture isolate (GISAID accession numbers EPI_ISL_410545 and EPI_ISL_410546). At admission, no other respiratory infections were detected (QIAstat-Dx Respiratory Panel; Qiagen).

Published
2020

5. Clinical management of imported malaria in Italy: Results from a national cross-sectional survey in 2015

Author

Lepore, L, Vairo, F, D'Abramo, A, Grilli, E, Corpolongo, A, Scorzolini, L, Nisii, C, Calleri, G, Castelli, F, Chirianni, A, Ippolito, G, Nicastri, E, Andreoni, M, Angarano, G, Anselmo, M, Ascoli Bartoli, T, Bartoloni, A, Bassi, P, Bevilacqua, N, Bisoffi, Z, Cacopardo, B, Caligaris, S, Calzetti, C, Casolari, S, Cassola, G, Chianura, L, Chiodera, A, Conforto, M, Coppola, N, De Luca, A, Feasi, M, Ferrari, C, Filippini, P, Foti, G, Francavilla, E, Fusco, F, Tekle, S, Giancola, M, Giammario, A, Giobbia, M, Giordani, M, Gobbi, F, Gori, A, Grossi, P, Iacobello, C, Iannetta, M, Libanore, M, Luzzati, R, Magnani, G, Manfrin, V, Mariano, A, Mastroianni, C, Mazzotta, F, Mecocci, L, Mondardini, V, Montineri, A, Nicolini, L, Oliva, A, Palazzolo, C, Pasquale, G, Portelli, V, Puoti, M, Quirino, T, Santantonio, T, Sarmati, L, Sciotti, M, Scotton, P, Tomasoni, L, Toscanini, F, Tunesi, S, Vanino, E, Viale, P, Vigano, P, Viscoli, C, Vullo, V, Lepore L., Vairo F., D'Abramo A., Grilli E., Corpolongo A., Scorzolini L., Nisii C., Calleri G., Castelli F., Chirianni A., Ippolito G., Nicastri E., Andreoni M., Angarano G., Anselmo M., Ascoli Bartoli T., Bartoloni A., Bassi P., Bevilacqua N., Bisoffi Z., Cacopardo B., Caligaris S., Calzetti C., Casolari S., Cassola G., Chianura L., Chiodera A., Conforto M., Coppola N., De Luca A., Feasi M., Ferrari C., Filippini P., Foti G., Francavilla E., Fusco F. M., Tekle S. G., Giancola M. L., Giammario A., Giobbia M., Giordani M. T., Gobbi F., Gori A., Grossi P., Iacobello C., Iannetta M., Libanore M., Luzzati R., Magnani G., Manfrin V., Mariano A., Mastroianni C., Mazzotta F., Mecocci L., Mondardini V., Montineri A., Nicolini L. A., Oliva A., Palazzolo C., Pasquale G., Portelli V., Puoti M., Quirino T., Santantonio T. A., Sarmati L., Sciotti M. P., Scotton P., Tomasoni L. R., Toscanini F., Tunesi S., Vanino E., Viale P., Vigano P., Viscoli C., Vullo V., Lepore, L, Vairo, F, D'Abramo, A, Grilli, E, Corpolongo, A, Scorzolini, L, Nisii, C, Calleri, G, Castelli, F, Chirianni, A, Ippolito, G, Nicastri, E, Andreoni, M, Angarano, G, Anselmo, M, Ascoli Bartoli, T, Bartoloni, A, Bassi, P, Bevilacqua, N, Bisoffi, Z, Cacopardo, B, Caligaris, S, Calzetti, C, Casolari, S, Cassola, G, Chianura, L, Chiodera, A, Conforto, M, Coppola, N, De Luca, A, Feasi, M, Ferrari, C, Filippini, P, Foti, G, Francavilla, E, Fusco, F, Tekle, S, Giancola, M, Giammario, A, Giobbia, M, Giordani, M, Gobbi, F, Gori, A, Grossi, P, Iacobello, C, Iannetta, M, Libanore, M, Luzzati, R, Magnani, G, Manfrin, V, Mariano, A, Mastroianni, C, Mazzotta, F, Mecocci, L, Mondardini, V, Montineri, A, Nicolini, L, Oliva, A, Palazzolo, C, Pasquale, G, Portelli, V, Puoti, M, Quirino, T, Santantonio, T, Sarmati, L, Sciotti, M, Scotton, P, Tomasoni, L, Toscanini, F, Tunesi, S, Vanino, E, Viale, P, Vigano, P, Viscoli, C, Vullo, V, Lepore L., Vairo F., D'Abramo A., Grilli E., Corpolongo A., Scorzolini L., Nisii C., Calleri G., Castelli F., Chirianni A., Ippolito G., Nicastri E., Andreoni M., Angarano G., Anselmo M., Ascoli Bartoli T., Bartoloni A., Bassi P., Bevilacqua N., Bisoffi Z., Cacopardo B., Caligaris S., Calzetti C., Casolari S., Cassola G., Chianura L., Chiodera A., Conforto M., Coppola N., De Luca A., Feasi M., Ferrari C., Filippini P., Foti G., Francavilla E., Fusco F. M., Tekle S. G., Giancola M. L., Giammario A., Giobbia M., Giordani M. T., Gobbi F., Gori A., Grossi P., Iacobello C., Iannetta M., Libanore M., Luzzati R., Magnani G., Manfrin V., Mariano A., Mastroianni C., Mazzotta F., Mecocci L., Mondardini V., Montineri A., Nicolini L. A., Oliva A., Palazzolo C., Pasquale G., Portelli V., Puoti M., Quirino T., Santantonio T. A., Sarmati L., Sciotti M. P., Scotton P., Tomasoni L. R., Toscanini F., Tunesi S., Vanino E., Viale P., Vigano P., Viscoli C., and Vullo V.

Abstract

In Italy, malaria continues to be one of the most common imported parasitoses; therefore, continuous surveillance of epidemiological data and clinical management is needed. In 2016, the National Institute for Infectious Diseases 'Lazzaro Spallanzani' in Rome promoted a retrospective questionnaire-based survey to assess the clinical management of imported malaria cases in Italy in 2015. The questionnaire was sent to 104 Tropical and/or Infectious Diseases Units in the country, and 37 of them filled out and returned the questionnaires. A total of 399 malaria cases were reported in 2015, mostly caused by Plasmodium falciparum and imported from Africa. Malaria chemoprophylaxis was correctly used by a minority of patients. Most patients presented with uncomplicated malaria and were treated orally. In severe cases, intravenous artesunate or quinine alone or in combination were administered, although one third of these severe cases received oral treatment. This retrospective survey reveals a lack of homogeneity in management of malaria-imported cases in Italy. Improvement of malaria chemoprophylaxis, standardization of clinical management of malaria cases and harmonization of oral and intravenous drug availability are needed throughout the country.

Published
2020

6. An inflammatory profile correlates with decreased frequency of cytotoxic cells in coronavirus disease 2019

Author

Bordoni, V., Sacchi, A., Cimini, E., Notari, S., Grassi, G., Tartaglia, E., Casetti, R., Giancola, M. L., Bevilacqua, N., Maeurer, M., Zumla, A., Locatelli, Franco, De Benedetti, F., Palmieri, F., Marchioni, L., Capobianchi, M. R., D'Offizi, G., Petrosillo, N., Antinori, A., Nicastri, E., Ippolito, G., Agrati, C., Locatelli F. (ORCID:0000-0002-7976-3654), Bordoni, V., Sacchi, A., Cimini, E., Notari, S., Grassi, G., Tartaglia, E., Casetti, R., Giancola, M. L., Bevilacqua, N., Maeurer, M., Zumla, A., Locatelli, Franco, De Benedetti, F., Palmieri, F., Marchioni, L., Capobianchi, M. R., D'Offizi, G., Petrosillo, N., Antinori, A., Nicastri, E., Ippolito, G., Agrati, C., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Increased production of inflammatory cytokines and myeloid-derived suppressor cells occurs in patients with coronavirus disease 2019. These inversely correlated with perforin-expressing natural killer (NK) and CD3+ T cells. We observed a lower number of perforin-expressing NK cells in intensive care unit (ICU) patients compared with non-ICU patients, suggesting an impairment of the immune cytotoxic arm as a pathogenic mechanism.

Published
2020

7. JCV-specific T-cells producing IFN-gamma are differently associated with PmL occurrence in HIV patients and liver transplant recipients

Author

Chiara Agrati, Izzo, L., Berno, G., Cimini, E., Bordoni, V., Giancola, M. L., Baldini, F., Colasanti, M., Ettorre, G. M., Izzo, P., Pugliese, F., Angrisani, M., Di Cello, P., Capobianchi, M. R., and Bolognese, A.

Subjects
Adult, Male, complications, isolation & purification, etiology, T-Lymphocytes, HIV Infections, Progressive Multifocal, HIV Infections, complications, HIV Infections, immunology, HIV Infections, surgery, HIV Infections, virology, HIV-1, genetics, HIV-1, immunology, Interferon-gamma, genetics, Interferon-gamma,immunology, JC Virus, genetics, JC Virus, immunology, JC Virus, isolation & purification, Leukoencephalopathy, Progressive Multifocal, etiology, Leukoencephalopathy, Progressive Multifocal, immunology, Leukoencephalopathy, Progressive Multifocal, virology, Liver Transplantation, T-Lymphocytes, immunology, T-Lymphocytes, virology, Transplant Recipients, surgery, immunology, Interferon-gamma, Leukoencephalopathy, Humans, genetics, Aged, Leukoencephalopathy, Progressive Multifocal, Middle Aged, JC Virus, virology, HIV-1, Female
Abstract

Aim of this work was to investigate a possible correlation between the frequency of JCV-specific T-cells and PML occurrence in HIV-infected subjects and in liver transplant recipients. A significant decrease of JCV-specific T-cells was observed in HIV-PML subjects, highlighting a close relation between JCV-specific T-cell immune impairment and PML occurrence in HIV-subjects. Interestingly, liver-transplant recipients (LTR) showed a low frequency of JCV-specific T-cells, similar to HIV-PML subjects. Nevertheless, none of the enrolled LTR developed PML, suggesting the existence of different immunological mechanisms involved in the maintenance of a protective immune response in LTR.

Published
2014

9. Caratteristiche e sopravvivenza delle patologie neurologiche in HIV durante l’era della HAART: Dati del registro Italiano NeuroAIDS

Author

Amassari, A., Cinque, P., Soldani, F., Lorenzini, P., Toma, A., Govoni, A., Giancola, M. L., Grisetti, S., Pierotti, C., Cingolani, A, Finazzi, M. G., Vigo, B., Bini, T., Tozzi, V., Fausti, C., Cristiano, L., Foresti, S., Guaraldi, Giovanni, Monno, L., Corsi, P., Mazzarello, G., Gentile, M., Mena, M., Arcidiacono, M. I., Fasulo, G., d’Arminio Monforte, A., Rezza, G., Ippolito, G., and Antinori, A.

Subjects
HAART, HIV, patologie neurologiche
Published
2001

15. Clinical management of imported malaria in Italy: Results from a national cross-sectional survey in 2015

Author

Lepore, L., Vairo, F., D Abramo, A., Grilli, E., Corpolongo, A., Scorzolini, L., Nisii, C., Calleri, G., Castelli, F., Chirianni, A., Ippolito, G., Nicastri, E., Andreoni, M., Angarano, G., Anselmo, M., Ascoli Bartoli, T., Bartoloni, A., Bassi, P., Bevilacqua, N., Bisoffi, Z., Cacopardo, B., Caligaris, S., Calzetti, C., Casolari, S., Cassola, G., Chianura, L., Chiodera, A., Conforto, M., Coppola, N., Luca, A., Feasi, M., Ferrari, C., Filippini, P., Foti, G., Francavilla, E., Fusco, F. M., Tekle, S. G., Giancola, M. L., Giammario, A., Giobbia, M., Giordani, M. T., Gobbi, F., Gori, A., Grossi, P., Iacobello, C., Iannetta, M., Libanore, M., Luzzati, R., Magnani, G., Manfrin, V., Mariano, A., Mastroianni, C., Mazzotta, F., Mecocci, L., Mondardini, V., Montineri, A., Nicolini, L. A., Oliva, A., Palazzolo, C., Pasquale, G., Portelli, V., Puoti, M., Quirino, T., Santantonio, T. A., Sarmati, L., Sciotti, M. P., Scotton, P., Tomasoni, L. R., Toscanini, F., Tunesi, S., Elisa Vanino, Viale, P., Viganò, P., Viscoli, C., Vullo, V., Lepore, L., Vairo, F., D'Abramo, A., Grilli, E., Corpolongo, A., Scorzolini, L., Nisii, C., Calleri, G., Castelli, F., Chirianni, A., Ippolito, G., Nicastri, E., Andreoni, M., Angarano, G., Anselmo, M., Ascoli Bartoli, T., Bartoloni, A., Bassi, P., Bevilacqua, N., Bisoffi, Z., Cacopardo, B., Caligaris, S., Calzetti, C., Casolari, S., Cassola, G., Chianura, L., Chiodera, A., Conforto, M., Coppola, N., De Luca, A., Feasi, M., Ferrari, C., Filippini, P., Foti, G., Francavilla, E., Fusco, F. M., Tekle, S. G., Giancola, M. L., Giammario, A., Giobbia, M., Giordani, M. T., Gobbi, F., Gori, A., Grossi, P., Iacobello, C., Iannetta, M., Libanore, M., Luzzati, R., Magnani, G., Manfrin, V., Mariano, A., Mastroianni, C., Mazzotta, F., Mecocci, L., Mondardini, V., Montineri, A., Nicolini, L. A., Oliva, A., Palazzolo, C., Pasquale, G., Portelli, V., Puoti, M., Quirino, T., Santantonio, T. A., Sarmati, L., Sciotti, M. P., Scotton, P., Tomasoni, L. R., Toscanini, F., Tunesi, S., Vanino, E., Viale, P., Vigano, P., Viscoli, C., and Vullo, V.

Subjects
Plasmodium, Travel, Clinical Management, Imported Malaria, Italian National Survey, Plasmodium falciparum, Malaria, Antimalarials, Cross-Sectional Studies, Humans, Italy, Retrospective Studies, Surveys and Questionnaires
Abstract

In Italy, malaria continues to be one of the most common imported parasitoses; therefore, continuous surveillance of epidemiological data and clinical management is needed. In 2016, the National Institute for Infectious Diseases 'Lazzaro Spallanzani' in Rome promoted a retrospective questionnaire-based survey to assess the clinical management of imported malaria cases in Italy in 2015. The questionnaire was sent to 104 Tropical and/or Infectious Diseases Units in the country, and 37 of them filled out and returned the questionnaires. A total of 399 malaria cases were reported in 2015, mostly caused by Plasmodium falciparum and imported from Africa. Malaria chemoprophylaxis was correctly used by a minority of patients. Most patients presented with uncomplicated malaria and were treated orally. In severe cases, intravenous artesunate or quinine alone or in combination were administered, although one third of these severe cases received oral treatment. This retrospective survey reveals a lack of homogeneity in management of malaria-imported cases in Italy. Improvement of malaria chemoprophylaxis, standardization of clinical management of malaria cases and harmonization of oral and intravenous drug availability are needed throughout the country.

16. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA)

Author

Antinori, A., Cingolani, A., Lorenzini, P., Giancola, M. L., Uccella, I., Bossolasco, S., Grisetti, S., Moretti, F., Vigo, B., Bongiovanni, M., Del Grosso, B., Arcidiacono, M. I., Fibbia, G. C., Mena, M., Finazzi, M. G., Guaraldi, G., Ammassari, A., D Arminio Monforte, A., Cinque, P., Luca, A., Burzacchini, F., Mecocci, L., Giorni, P., Monno, L., Fasulo, G., Moling, O., Brighi, S., Sighinolfi, L., Corsi, P., Di Toro, M. T., Mastroianni, A., Simone, M., Mazzarello, G., Carli, T., Artioli, S., Vetica, A., Congedo, P., Zannoni, P., Foresti, S., Figoni, M., Dallenogare, E. R., Rotondo, G., Agostinone, A., Mariano, A., Donisi, A., Vivarelli, A., Loiacono, L., Gigli, B., Larussa, D., maria rosa ciardi, Viviani, F., Palumbo, M., Cristiano, L., and Speranza, F.

18. Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome

Author

Serena Vita, Virginia Di Bari, Angela Corpolongo, Delia Goletti, Joaquin Espinosa, Sebastiano Petracca, Fabrizio Palmieri, Emanuele Nicastri, null Abbonizio, Chiara Agrati, Fabrizio Albarello, Gioia Amadei, Alessandra Amendola, Mario Antonini, Raffaella Barbaro, Barbara Bartolini, Martina Benigni, Nazario Bevilacqua, Licia Bordi, Veronica Bordoni, Marta Branca, Paolo Campioni, Maria Rosaria Capobianchi, Cinzia Caporale, Ilaria Caravella, Fabrizio Carletti, Concetta Castilletti, Roberta Chiappini, Carmine Ciaralli, Francesca Colavita, Massimo Cristofaro, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Rachele Di Lorenzo, Federica Di Stefano, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Paola Gallì, Gabriele Garotto, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Maria Cristina Greci, Giuseppe Ippolito, Eleonora Lalle, Simone Lanini, Daniele Lapa, Luciana Lepore, Andrea Lucia, Franco Lufrani, Manuela Macchione, Alessandra Marani, Luisa Marchioni, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Giulia Matusali, Silvia Meschi, Francesco Messina Chiara Montaldo, Silvia Murachelli, Roberto Noto, Claudia Palazzolo, Emanuele Pallini, Virgilio Passeri, Federico Pelliccioni, Antonella Petrecchia, Ada Petrone, Nicola Petrosillo, Elisa Pianura, Maria Pisciotta, Silvia Pittalis, Costanza Proietti, Vincenzo Puro, Gabriele Rinonapoli, Martina Rueca, Alessandra Sacchi, Francesco Sanasi, Carmen Santagata, Silvana Scarcia, Vincenzo Schininà, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Francesco Vaia, Francesco Vairo, Maria Beatrice Valli, Vita, S., Di Bari, V., Corpolongo, A., Goletti, D., Espinosa, J., Petracca, S., Palmieri, F., Nicastri, E., Abbonizio, Agrati, C., Albarello, F., Amadei, G., Amendola, A., Antonini, M., Barbaro, R., Bartolini, B., Benigni, M., Bevilacqua, N., Bordi, L., Bordoni, V., Branca, M., Campioni, P., Capobianchi, M. R., Caporale, C., Caravella, I., Carletti, F., Castilletti, C., Chiappini, R., Ciaralli, C., Colavita, F., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., Angelis, A. D., Angelis, G. D., Lorenzo, R. D., Stefano, F. D., Ferraro, F., Fiorentini, L., Frustaci, A., Galli, P., Garotto, G., Giancola, M. L., Giansante, F., Giombini, E., Greci, M. C., Ippolito, G., Lalle, E., Lanini, S., Lapa, D., Lepore, L., Lucia, A., Lufrani, F., Macchione, M., Marani, A., Marchioni, L., Mariano, A., Marini, M. C., Maritti, M., Matusali, G., Meschi, S., Montaldo, F. M. C., Murachelli, S., Noto, R., Palazzolo, C., Pallini, E., Passeri, V., Pelliccioni, F., Petrecchia, A., Petrone, A., Petrosillo, N., Pianura, E., Pisciotta, M., Pittalis, S., Proietti, C., Puro, V., Rinonapoli, G., Rueca, M., Sacchi, A., Sanasi, F., Santagata, C., Scarcia, S., Schinina, V., Scognamiglio, P., Scorzolini, L., Stazi, G., Vaia, F., Vairo, F., and Valli, M. B.

Subjects
0301 basic medicine, Microbiology (medical), Pediatrics, medicine.medical_specialty, Down syndrome, immuneactivation, 030106 microbiology, Case Report, medicine.disease_cause, NO, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, Clinical significance, lcsh:RC109-216, 030212 general & internal medicine, COVID-19 pneumonia, ComputingMethodologies_COMPUTERGRAPHICS, Coronavirus, Immune activation, business.industry, General Medicine, Immune dysregulation, medicine.disease, Vaccination, Pneumonia, Infectious Diseases, medicine.anatomical_structure, business, Trisomy, Respiratory tract
Abstract

Graphical abstract, Highlights • Pro-inflammatory factors play a central role in COVID-19 severity and mortality. • Down Syndrome is characterized by immune dysregulation and respiratory infections. • Down Syndrome patients with COVID-19 are at high-risk for unfavourable outcome., We report two cases of COronaVIrus Disease-19 in patients with Down Syndrome and describe the identification, diagnosis, clinical course, and management of the infection. Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and higher rate of comorbidities. All these risk factors can contribute to more severe clinical presentations of COVID-19. It is essential to raise awareness of the clinical relevance of SARS-COV-2 infection in DS patients, as well in other most vulnerable patients in order to improve their management and treatment and to candidate these individuals for vaccination, once available.

Published
2021

19. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation

Author

Fabrizio Albarello, Elisa Pianura, Federica Di Stefano, Massimo Cristofaro, Ada Petrone, Luisa Marchioni, Claudia Palazzolo, Vincenzo Schininà, Emanuele Nicastri, Nicola Petrosillo, Paolo Campioni, Petersen Eskild, Alimuddin Zumla, Giuseppe Ippolito, Maria Alessandra Abbonizio, Chiara Agrati, Gioia Amadei, Alessandra Amendola, Mario Antonini, Raffaella Barbaro, Barbara Bartolini, Martina Benigni, Nazario Bevilacqua, Licia Bordi, Veronica Bordoni, Marta Branca, Maria Rosaria Capobianchi, Cinzia Caporale, Ilaria Caravella, Fabrizio Carletti, Concetta Castilletti, Roberta Chiappini, Carmine Ciaralli, Francesca Colavita, Angela Corpolongo, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Rachele Di Lorenzo, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Paola Gallì, Gabriele Garotto, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Maria Cristina Greci, Eleonora Lalle, Simone Lanini, Daniele Lapa, Luciana Lepore, Andrea Lucia, Franco Lufrani, Manuela Macchione, Alessandra Marani, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Giulia Matusali, Silvia Meschi, Francesco Messina Chiara Montaldo, Silvia Murachelli, Roberto Noto, Emanuele Pallini, Virgilio Passeri, Federico Pelliccioni, Antonella Petrecchia, Maria Pisciotta, Silvia Pittalis, Costanza Proietti, Vincenzo Puro, Gabriele Rinonapoli, Martina Rueca, Alessandra Sacchi, Francesco Sanasi, Carmen Santagata, Silvana Scarcia, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Francesco Vaia, Francesco Vairo, Maria Beatrice Valli, Albarello, F., Pianura, E., Di Stefano, F., Cristofaro, M., Petrone, A., Marchioni, L., Palazzolo, C., Schinina, V., Nicastri, E., Petrosillo, N., Campioni, P., Eskild, P., Zumla, A., Ippolito, G., Abbonizio, M. A., Agrati, C., Amadei, G., Amendola, A., Antonini, M., Barbaro, R., Bartolini, B., Benigni, M., Bevilacqua, N., Bordi, L., Bordoni, V., Branca, M., Capobianchi, M. R., Caporale, C., Caravella, I., Carletti, F., Castilletti, C., Chiappini, R., Ciaralli, C., Colavita, F., Corpolongo, A., Curiale, S., D'Abramo, A., Dantimi, C., Angelis, A. D., Angelis, G. D., Lorenzo, R. D., Stefano, F. D., Ferraro, F., Fiorentini, L., Frustaci, A., Galli, P., Garotto, G., Giancola, M. L., Giansante, F., Giombini, E., Greci, M. C., Lalle, E., Lanini, S., Lapa, D., Lepore, L., Lucia, A., Lufrani, F., Macchione, M., Marani, A., Mariano, A., Marini, M. C., Maritti, M., Matusali, G., Meschi, S., Montaldo, F. M. C., Murachelli, S., Noto, R., Pallini, E., Passeri, V., Pelliccioni, F., Petrecchia, A., Pisciotta, M., Pittalis, S., Proietti, C., Puro, V., Rinonapoli, G., Rueca, M., Sacchi, A., Sanasi, F., Santagata, C., Scarcia, S., Scognamiglio, P., Scorzolini, L., Stazi, G., Vaia, F., Vairo, F., and Valli, M. B.

Subjects
0301 basic medicine, ARDS, medicine.disease_cause, 0302 clinical medicine, SARS-COV2, 030212 general & internal medicine, Lung, Respiratory Distress Syndrome, Respiratory distress, Ground glass opacitie, General Medicine, Crazy-paving, Infectious Diseases, medicine.anatomical_structure, Italy, Severe acute respiratory syndrome-related coronavirus, Radiological weapon, Disease Progression, Middle East Respiratory Syndrome Coronavirus, Radiology, medicine.symptom, Presentation (obstetrics), Coronavirus Infections, Ground glass opacities, Adult, Microbiology (medical), China, medicine.medical_specialty, Mediastinal lymphadenopathy, Middle East respiratory syndrome coronavirus, Pneumonia, Viral, 030106 microbiology, Article, NO, lcsh:Infectious and parasitic diseases, Lesion, Betacoronavirus, 03 medical and health sciences, medicine, Humans, LS7_2, lcsh:RC109-216, Pandemics, Enlarged pulmonary vessel, SARS-CoV-2, business.industry, COVID-19, CT-scan, Enlarged pulmonary vessels, medicine.disease, Tomography, X-Ray Computed, business
Abstract

Highlights • The first two patients identified in Italy with COVID-19 presented remarkable imaging findings who progressed in adult respiratory distress syndrome. • Uncommon elements such as pleural effusions, a tubular and enlarged appearance of pulmonary vessels with a sudden caliber reduction and mediastinal lymphadenopathy were noted during the follow-up. • The vessels appearance during the follow up, resembling a “feeding vessel sign”, could be an early alert radiological sign to predict initial lung deterioration., Introduction Several recent case reports have described common early chest imaging findings of lung pathology caused by 2019 novel Coronavirus (SARS-COV2) which appear to be similar to those seen previously in SARS-CoV and MERS-CoV infected patients. Objective We present some remarkable imaging findings of the first two patients identified in Italy with COVID-19 infection travelling from Wuhan, China. The follow-up with chest X-Rays and CT scans was also included, showing a progressive adult respiratory distress syndrome (ARDS). Results Moderate to severe progression of the lung infiltrates, with increasing percentage of high-density infiltrates sustained by a bilateral and multi-segmental extension of lung opacities, were seen. During the follow-up, apart from pleural effusions, a tubular and enlarged appearance of pulmonary vessels with a sudden caliber reduction was seen, mainly found in the dichotomic tracts, where the center of a new insurgent pulmonary lesion was seen. It could be an early alert radiological sign to predict initial lung deterioration. Another uncommon element was the presence of mediastinal lymphadenopathy with short-axis oval nodes. Conclusions Although only two patients have been studied, these findings are consistent with the radiological pattern described in literature. Finally, the pulmonary vessels enlargement in areas where new lung infiltrates develop in the follow-up CT scan, could describe an early predictor radiological sign of lung impairment.

Published
2020
Full Text
View/download PDF

20. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted in an Italian Reference Hospital

Author

Annalisa Mondi, Patrizia Lorenzini, Concetta Castilletti, Roberta Gagliardini, Eleonora Lalle, Angela Corpolongo, Maria Beatrice Valli, Fabrizio Taglietti, Stefania Cicalini, Laura Loiacono, Francesco Di Gennaro, Gianpiero D’Offizi, Fabrizio Palmieri, Emanuele Nicastri, Chiara Agrati, Nicola Petrosillo, Giuseppe Ippolito, Francesco Vaia, Enrico Girardi, Maria Rosaria Capobianchi, Andrea Antinori, Sara Zito, Maria Alessandra Abbonizio, Amina Abdeddaim, Elisabetta Agostini, Fabrizio Albarello, Gioia Amadei, Alessandra Amendola, Maria Assunta Antonica, Mario Antonini, Tommaso Ascoli Bartoli, Francesco Baldini, Raffaella Barbaro, Barbara Bartolini, Rita Bellagamba, Martina Benigni, Nazario Bevilacqua, Gianluigi Biava, Michele Bibas, Licia Bordi, Veronica Bordoni, Evangelo Boumis, Marta Branca, Rosanna Buonomo, Donatella Busso, Marta Camici, Paolo Campioni, Flaminia Canichella, Alessandro Capone, Cinzia Caporale, Emanuela Caraffa, Ilaria Caravella, Fabrizio Carletti, Adriana Cataldo, Stefano Cerilli, Carlotta Cerva, Roberta Chiappini, Pierangelo Chinello, Maria Assunta Cianfarani, Carmine Ciaralli, Claudia Cimaglia, Nicola Cinicola, Veronica Ciotti, Francesca Colavita, Massimo Cristofaro, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Maria Grazia De Palo, Federico De Zottis, Virginia Di Bari, Rachele Di Lorenzo, Federica Di Stefano, Davide Donno, Francesca Evangelista, Francesca Faraglia, Anna Farina, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Matteo Fusetti, Vincenzo Galati, Paola Gallì, Gabriele Garotto, Ilaria Gaviano, Saba Gebremeskel Tekle, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Guido Granata, Maria Cristina Greci, Elisabetta Grilli, Susanna Grisetti, Gina Gualano, Fabio Iacomi, Marta Iaconi, Giuseppina Iannicelli, Carlo Inversi, Maria Elena Lamanna, Simone Lanini, Daniele Lapa, Luciana Lepore, Raffaella Libertone, Raffaella Lionetti, Giuseppina Liuzzi, Andrea Lucia, Franco Lufrani, Manuela Macchione, Gaetano Maffongelli, Alessandra Marani, Luisa Marchioni, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Annelisa Mastrobattista, Ilaria Mastrorosa, Giulia Matusali, Valentina Mazzotta, Paola Mencarini, Silvia Meschi, Francesco Messina, Sibiana Micarelli, Giulia Mogavero, Marzia Montalbano, Chiara Montaldo, Silvia Mosti, Silvia Murachelli, Maria Musso, Michela Nardi, Assunta Navarra, Martina Nocioni, Pasquale Noto, Roberto Noto, Alessandra Oliva, Ilaria Onnis, Sandrine Ottou, Claudia Palazzolo, Emanuele Pallini, Giulio Palombi, Carlo Pareo, Virgilio Passeri, Federico Pelliccioni, Giovanna Penna, Antonella Petrecchia, Ada Petrone, Elisa Pianura, Carmela Pinnetti, Maria Pisciotta, Pierluca Piselli, Silvia Pittalis, Agostina Pontarelli, Costanza Proietti, Vincenzo Puro, Paolo Migliorisi Ramazzini, Alessia Rianda, Gabriele Rinonapoli, Silvia Rosati, Dorotea Rubino, Martina Rueca, Alberto Ruggeri, Alessandra Sacchi, Alessandro Sampaolesi, Francesco Sanasi, Carmen Santagata, Alessandra Scarabello, Silvana Scarcia, Vincenzo Schininà, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Giacomo Strano, Chiara Taibi, Giorgia Taloni, Tetaj Nardi, Roberto Tonnarini, Simone Topino, Martina Tozzi, Francesco Vairo, Alessandra Vergori, Laura Vincenzi, Ubaldo Visco-Comandini, Serena Vita, Pietro Vittozzi, Mauro Zaccarelli, Antonella Zanetti, Mondi, A., Lorenzini, P., Castilletti, C., Gagliardini, R., Lalle, E., Corpolongo, A., Valli, M. B., Taglietti, F., Cicalini, S., Loiacono, L., Di Gennaro, F., D'Offizi, G., Palmieri, F., Nicastri, E., Agrati, C., Petrosillo, N., Ippolito, G., Vaia, F., Girardi, E., Capobianchi, M. R., Antinori, A., Zito, S., Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Campioni, P., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., Donno, D., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Galati, V., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Gualano, G., Iacomi, F., Iaconi, M., Iannicelli, G., Inversi, C., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Marchioni, L., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Schinina, V., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Vergori, A., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., and Zanetti, A.

Subjects
Male, 0301 basic medicine, Time Factors, medicine.medical_treatment, Respiratory System, coronavirus, Infectious and parasitic diseases, RC109-216, Severity of Illness Index, Cohort Studies, 0302 clinical medicine, risk factors, 030212 general & internal medicine, Respiratory disease, General Medicine, Middle Aged, Virus Shedding, Infectious Diseases, symbols, RNA, Viral, Female, Coronavirus, COVID-19, viral clearance, viral shedding, Risk factors, SARS-CoV-2, Cohort study, Adult, Microbiology (medical), medicine.medical_specialty, viral shedding, Coronaviru, 030106 microbiology, Article, NO, 03 medical and health sciences, symbols.namesake, Internal medicine, Severity of illness, medicine, Humans, Poisson regression, Aged, Proportional Hazards Models, Mechanical ventilation, business.industry, Proportional hazards model, COVID-19, Retrospective cohort study, medicine.disease, Respiratory failure, Risk factor, business, viral clearance
Abstract

Background Few data about predictors and outcomes associated with prolonged SARS-CoV-2 RNA shedding (VS) are available. Methods Retrospective study including all patients admitted with COVID-19 in an Italian reference hospital for infectious diseases between March 1 and July 1, 2020. Predictors of viral clearance (VC) and prolonged VS from upper respiratory tract were assessed by Poisson regression and logistic regression analyses. The causal relation between duration of VS and probability of clinical outcomes was evaluated through inverse probability weighted Cox model. Results 536 subjects were included. Median duration of VS from symptoms onset was 18 days (IQR 12-26). The estimated 30-day probability of VC was 70.2% (95%CI:65-75). At multivariable analysis, patients with comorbidities (aIRR = 0.88, p = 0.004), lymphopenia at hospital admission (aIRR = 0.75, p = 0.032) and with moderate/severe respiratory disease (aIRR = 0.42, p 1000 ng/mL at admission (aOR = 1.76, p = 0.035) independently predicted prolonged VS. The achievement of VC doubled the chance of clinical recovery (aHR = 2.17, p

Published
2021

21. An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019

Author

Alessandra Sacchi, Fabrizio De Benedetti, Markus Maeurer, Fabrizio Palmieri, Franco Locatelli, Nazario Bevilacqua, Maria Rosaria Capobianchi, Eleonora Cimini, Eleonora Tartaglia, Chiara Agrati, Emanuele Nicastri, Nicola Petrosillo, Rita Casetti, Gianpiero D'Offizi, Alimuddin Zumla, Giuseppe Ippolito, Andrea Antinori, Stefania Notari, Veronica Bordoni, Luisa Marchioni, Germana Grassi, Maria Letizia Giancola, Bordoni, V., Sacchi, A., Cimini, E., Notari, S., Grassi, G., Tartaglia, E., Casetti, R., Giancola, M. L., Bevilacqua, N., Maeurer, M., Zumla, A., Locatelli, F., De Benedetti, F., Palmieri, F., Marchioni, L., Capobianchi, M. R., D'Offizi, G., Petrosillo, N., Antinori, A., Nicastri, E., Ippolito, G., and Agrati, C.

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_treatment, MDSC, Inflammation, chemical and pharmacologic phenomena, NK cells, Proinflammatory cytokine, Natural killer cell, 03 medical and health sciences, 0302 clinical medicine, Immune system, medicine, Cytotoxic T cell, cytotoxic cell, cytotoxic cells, biology, business.industry, COVID-19, inflammation, 030104 developmental biology, medicine.anatomical_structure, Cytokine, Infectious Diseases, Perforin, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, 030220 oncology & carcinogenesis, Immunology, biology.protein, Myeloid-derived Suppressor Cell, medicine.symptom, business
Abstract

Increased production of inflammatory cytokines and myeloid-derived suppressor cells occurs in patients with coronavirus disease 2019. These inversely correlated with perforin-expressing natural killer (NK) and CD3+ T cells. We observed a lower number of perforin-expressing NK cells in intensive care unit (ICU) patients compared with non-ICU patients, suggesting an impairment of the immune cytotoxic arm as a pathogenic mechanism.

Published
2020
Full Text
View/download PDF

22. Dengue encephalitis presenting with nonconvulsive status epilepticus: A case report.

Author

Assenza F, Tombini M, Assenza G, Campana C, Benvenga A, Brunelli N, Ulivi M, Rizzo AC, Corpolongo A, Giancola ML, Nicastri E, and Di Lazzaro V

Subjects
Aged, Dengue complications, Encephalitis, Viral complications, Humans, Male, Status Epilepticus etiology, Dengue diagnosis, Dengue Virus pathogenicity, Encephalitis, Viral diagnosis, Status Epilepticus diagnosis
Published
2016
Full Text
View/download PDF

23. Pulmonary tuberculosis followed by sarcoidosis in an HIV-infected patient: A case report and a simplified diagnostic flowchart for diagnosis and treatment of sarcoidosis.

Author

Mencarini P, Bellagamba R, Oliva A, Ghirga P, Giancola ML, Corpolongo A, Ascoli Bartoli T, De Nardo P, Baiocchini A, Del Nonno F, Narciso P, and Nicastri E

Abstract

The diagnosis of sarcoidosis in a patient living with HIV infection is an uncommon event and a challenge for clinicians. Clinical manifestations are variable and fluctuating depending to adherence to ARV therapy and to the level of CD4 count. We analyze here one chronic case in which sarcoidosis appeared clinically two years after pulmonary tuberculosis. The course of the disease was influenced and prolonged by frequent interruptions of antiretroviral therapy. Moreover the diagnosis and the decision to treat have been delayed by the need of exclusion of other pathologies, principally tuberculosis reactivation/reinfection, other mycobacterial diseases, hematologic malignancies. We propose a simplified flowchart for diagnosis and follow up of sarcoidosis, which may also be applied to patients with HIV infection. Diagnosis of latent tuberculosis infection (LTBI) may be difficult in these patients, because the immunological paradox of sarcoidosis. For this reason, following exclusion of active tuberculosis, we advise to submit all sarcoidosis patients to IPT (isoniazid preventive therapy), when immunosuppressive therapy is started.

Published
2016
Full Text
View/download PDF

24. Cardiomyopathy and encephalopathy in AIDS.

Author

Antinori A, Giancola ML, Alba L, Soldani F, and Grisetti S

Subjects
AIDS Dementia Complex drug therapy, Antiretroviral Therapy, Highly Active, Cardiomyopathies drug therapy, Humans, AIDS Dementia Complex etiology, Acquired Immunodeficiency Syndrome complications, Cardiomyopathies etiology, HIV-1
Abstract

HIV encephalopathy has been in the past years the most typical CNS disorder in patients with AIDS. Histologic abnormalities consist in astrocytosis, myelin pallor, infiltration by infected macrophages, resident microglia and multinucleated giant cells, generally in absence of direct infection of neurons. Mononuclear phagocytes in the brain are the main target of HIV-1 infection and the site of productive viral replication, and viral stimulation leads to the release of neurotoxic products causing neurologic damage. Subclinical cardiac abnormalities are common in HIV+ patients and several studies suggested a role for cytokines and other inflammatory products as mediators of cardiac abnormalities. The common pathway for neurologic and cardiac manifestations supports the relationship between neurologic disease and cardiac dysfunction in HIV infection. Clinical observations suggest that cardiomyopathy could be associated with encephalopathy in HIV+ patients and that it may affect survival. Antiretroviral therapy may reduce impact of neurologic and cardiac abnormalities by suppressing plasma HIV-1 viral load.

Published
2001
Full Text
View/download PDF

25. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era.

Author

Antinori A, Ammassari A, Giancola ML, Cingolani A, Grisetti S, Murri R, Alba L, Ciancio B, Soldani F, Larussa D, Ippolito G, and De Luca A

Subjects
Acquired Immunodeficiency Syndrome mortality, Humans, Incidence, Prognosis, Prospective Studies, Registries, AIDS-Related Opportunistic Infections mortality, Acquired Immunodeficiency Syndrome drug therapy, Antiretroviral Therapy, Highly Active, Leukoencephalopathy, Progressive Multifocal mortality
Abstract

Whereas most AIDS-related neurologic disorders have reduced incidence since HAART therapy was introduced, we find that the incidence of progressive multifocal leukoencephalopathy (PML) did not significantly differ between the pre-HAART and the HAART period (OR 0.78; 95% CI 0.41-1.50). These findings were confirmed by the preliminary results of the Italian Register Investigative Neuro AIDS (IRINA) Study, a prospective multicenter study started in January 2000, which showed that PML was the second most frequently diagnosed neurologic disorder after TE. A similar proportion of cases were found in HAART-naïve and HAART-experienced patients in our experience. PML was more common in the presence of HIV RNA > 500 copies/ml. Most of the cases occurring in HAART-exposed patients developed within the first 6 months of therapy. As others have reported, we find a prolonged survival in PML subjects prescribed HAART (245 days in the group treated with HAART versus 66 days in the group not treated with HAART; P at log rank = 0.001). However despite the survival benefit, AIDS-associated PML still has a serious prognosis. In fact, PML had the lowest 1-year survival probability of any cerebral disorder in our study (P = 0.0005). Our findings also confirm that CSF JCV DNA burden at baseline is a useful prognostic indicator with a threshold of 4.7 log(10) JCV copies/ml (P at log rank = 0.01) in our experience. CSF JCV DNA load at 4 weeks of follow-up and clearance of JCV-DNA from CSF are associated with a better neurologic outcome and a longer survival.

Published
2001
Full Text
View/download PDF

26. Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study.

Author

De Luca A, Giancola ML, Ammassari A, Grisetti S, Cingolani A, Larussa D, Alba L, Murri R, Ippolito G, Cauda R, Monforte A, and Antinori A

Subjects
AIDS-Related Opportunistic Infections mortality, Acquired Immunodeficiency Syndrome drug therapy, Adult, Cidofovir, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Leukoencephalopathy, Progressive Multifocal mortality, Male, Middle Aged, Survival Rate, AIDS-Related Opportunistic Infections drug therapy, Antiretroviral Therapy, Highly Active, Antiviral Agents administration & dosage, Cytosine administration & dosage, Cytosine analogs & derivatives, Leukoencephalopathy, Progressive Multifocal drug therapy, Organophosphonates, Organophosphorus Compounds administration & dosage
Abstract

To analyze the clinical efficacy of cidofovir combined with highly active anti-retroviral therapy (HAART) in AIDS-related progressive multifocal leukoencepalopathy (PML), a multicenter observational study was performed. Consecutive HIV-positive patients with histologically or virologically proven PML and at least 4 weeks of treatment after diagnosis were examined: 27 patients were treated with HAART, whereas 16 patients were treated with HAART plus cidofovir 5 mg/kg intravenously per week for the first 2 weeks and every other week thereafter. JC virus DNA was quantified in cerebrospinal fluid (CSF) by PCR. Baseline virologic, immunologic, and clinical characteristics as well as HIV RNA and CD4 responses to HAART were homogeneous between the groups. The median follow-up was 132 weeks. In one case (6%), cidofovir was permanently discontinued because of severe proteinuria. One-year cumulative probability of survival was 0.61 with cidofovir and 0.29 without (log rank test P = 0.02). After adjusting for baseline CD4 counts, JC viral load in CSF, Karnofsky, and use of HAART prior to the onset of PML, the use of cidofovir was independently associated with a reduced risk of death (hazard ratio, 0.21, 95% confidence interval, 0.07-0.65; P = 0.005). A randomized study will definitively establish whether cidofovir confers significant advantage over HAART alone in AIDS-related PML.

Published
2001
Full Text
View/download PDF

27. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy.

Author

De Luca A, Giancola ML, Ammassari A, Grisetti S, Paglia MG, Gentile M, Cingolani A, Murri R, Liuzzi G, Monforte AD, and Antinori A

Subjects
AIDS Dementia Complex cerebrospinal fluid, AIDS Dementia Complex complications, Adult, Antiretroviral Therapy, Highly Active, Cerebrospinal Fluid virology, Female, Humans, Leukoencephalopathy, Progressive Multifocal complications, Male, Polymerase Chain Reaction, RNA, Viral blood, Retrospective Studies, Time Factors, Treatment Outcome, Viral Load, AIDS Dementia Complex drug therapy, Anti-HIV Agents therapeutic use, DNA, Viral cerebrospinal fluid, JC Virus isolation & purification, Leukoencephalopathy, Progressive Multifocal cerebrospinal fluid
Abstract

A multicenter analysis of 57 consecutive human immunodeficiency virus-positive patients with progressive multifocal leukoencephalopathy (PML) was performed, to identify correlates of longer survival. JC virus (JCV) DNA was quantified in the cerebrospinal fluid (CSF) by polymerase chain reaction. Two months after therapy, 4% of the patients without highly active antiretroviral therapy (HAART) and 26% with HAART showed neurologic improvement or stability (P=.03), and 8% and 57%, respectively, reached undetectable JCV DNA levels in the CSF (P=.04). One-year probability of survival was.04 without HAART and.46 with HAART. HAART and lack of neurologic progression 2 months after diagnosis were independently associated with longer survival. Among HAART-treated patients, a baseline JCV DNA <4.7 log, and reaching undetectable levels after therapy predicted longer survival. Survival of AIDS-related PML is improved by HAART when JCV replication is controlled.

Published
2000
Full Text
View/download PDF

28. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas.

Author

Cingolani A, Gastaldi R, Fassone L, Pierconti F, Giancola ML, Martini M, De Luca A, Ammassari A, Mazzone C, Pescarmona E, Gaidano G, Larocca LM, and Antinori A

Subjects
Adult, Central Nervous System Neoplasms cerebrospinal fluid, Central Nervous System Neoplasms epidemiology, Central Nervous System Neoplasms pathology, DNA, Viral cerebrospinal fluid, Epstein-Barr Virus Infections cerebrospinal fluid, Epstein-Barr Virus Infections epidemiology, Female, Herpesvirus 4, Human classification, Humans, Lymphoma, AIDS-Related cerebrospinal fluid, Lymphoma, AIDS-Related epidemiology, Lymphoma, AIDS-Related pathology, Lymphoma, Non-Hodgkin cerebrospinal fluid, Lymphoma, Non-Hodgkin epidemiology, Lymphoma, Non-Hodgkin pathology, Male, Predictive Value of Tests, Risk Factors, Central Nervous System Neoplasms virology, Epstein-Barr Virus Infections complications, Herpesvirus 4, Human genetics, Lymphoma, AIDS-Related virology, Lymphoma, Non-Hodgkin virology
Abstract

Purpose: This study aimed at correlating Epstein-Barr virus (EBV) infection of systemic AIDS-related non-Hodgkin lymphomas (AIDS-NHL) with the development of a CNS localization of the tumor., Patients and Methods: Demographic, epidemiologic, clinical, histologic, and virologic features were collected for all systemic AIDS-NHL patients included in the study (n = 50). Pathologic specimens were classified according to the working formulation for NHL and the Revised European-American Lymphoma classification. EBV infection in tumor tissue samples was studied by EBV small encoded RNA in situ hybridization; EBV-DNA detection in CSF was carried out by nested polymerase chain reaction using Epstein-Barr nuclear antigen-1-specific primers. In addition, selected EBV-positive lymphomas were subjected to a detailed characterization of EBV molecular heterogeneity., Results: Eleven patients had a CNS involvement at some point during their clinical history (four at diagnosis and seven at relapse). Thirty patients (11 with CNS involvement and 19 without) harbored EBV infection of the tumor. Sensitivity, specificity, and positive and negative predictive values of EBV-DNA detection in CSF for CNS involvement by lymphoma were 90%, 100%, 100%, and 97.6%, respectively. Factors significantly predictive of CNS involvement were EBV infection of the tumor (P=.003), an extranodal disease at diagnosis other than CNS (P=.006), and a non-CNS relapse (P=.01). In four cases of CNS involvement, EBV-DNA in CSF preceded any other sign of disease by a mean of 35 days., Conclusion: These results show that EBV infection of the tumor clone significantly increases the risk of CNS involvement by systemic AIDS-NHL, without regard of specific molecular features. The detection of EBV-DNA in the CSF of AIDS-NHL patients may select cases with higher risk of CNS involvement and, therefore, may prove useful in the therapeutic stratification of these tumors.

Published
2000
Full Text
View/download PDF

29. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy.

Author

De Luca A, Giancola ML, Ammassari A, Grisetti S, Cingolani A, Paglia MG, Govoni A, Murri R, Testa L, Monforte AD, and Antinori A

Subjects
Adult, Anti-HIV Agents adverse effects, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cerebrospinal Fluid virology, Cidofovir, Cytosine adverse effects, Cytosine analogs & derivatives, DNA, Viral analysis, Drug Therapy, Combination, Female, HIV isolation & purification, HIV Infections complications, HIV Seropositivity complications, HIV Seropositivity drug therapy, Humans, JC Virus isolation & purification, Leukoencephalopathy, Progressive Multifocal complications, Male, Middle Aged, Organophosphorus Compounds adverse effects, Proteinuria chemically induced, RNA, Viral analysis, Treatment Outcome, Anti-HIV Agents therapeutic use, Cytosine therapeutic use, HIV Infections drug therapy, Leukoencephalopathy, Progressive Multifocal drug therapy, Organophosphonates, Organophosphorus Compounds therapeutic use
Abstract

Objectives: To analyse the virological and clinical efficacy of cidofovir combined with highly active antiretroviral therapy (HAART) in AIDS-related progressive multifocal leukoencephalopathy (PML)., Design: Multicentre observational study of consecutive HIV-positive patients with histologically or virologically-proven PML. Group A, 26 patients treated with HAART; group B, 14 patients treated with HAART plus cidofovir 5 mg/kg intravenously per week for the first 2 weeks and alternate weeks thereafter. JC virus DNA was quantified in cerebrospinal fluid (CSF) by PCR., Results: Baseline virological, immunological and clinical characteristics were homogeneous between the groups. In one case cidofovir was discontinued because of severe proteinuria. There was no significant difference in HIV RNA responses and changes in the number of CD4 cells between group A and B. After 2 months of therapy, five out of 12 (42%) patients from group A and seven out of eight (87%) from group B reached undetectable JC virus DNA in the CSF (Chi-square P = 0.04); moreover, 24% of group A and 57% of group B patients showed neurological improvement or stability (P = 0.038). One-year cumulative probability of survival was 0.67 with cidofovir and 0.31 without (log-rank test, P = 0.01). Variables independently associated with longer survival were the use of cidofovir, HAART prior to the onset of PML, a baseline JC virus DNA load in CSF < 4.7 log10 copies/ml, and a baseline Karnofsky performance status > or = 60., Conclusions: In AIDS-related PML, cidofovir added to HAART is associated with a more effective control of JCV replication, with improved neurological outcome and survival compared with HAART alone.

Published
2000
Full Text
View/download PDF

30. Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: the effect of protease inhibitor therapy.

Author

De Luca A, Giancola ML, Cingolani A, Ammassari A, Murri R, and Antinori A

Subjects
CD4 Lymphocyte Count, Case-Control Studies, Chemokine CCL3, Chemokine CCL4, Chemokine CCL5 biosynthesis, Chemokine CCL5 blood, Chemokines, CC biosynthesis, HIV Infections virology, HIV-1 isolation & purification, Humans, In Vitro Techniques, Indinavir therapeutic use, Interferon-gamma biosynthesis, Interleukin-2 biosynthesis, Leukocytes, Mononuclear immunology, Macrophage Inflammatory Proteins biosynthesis, Macrophage Inflammatory Proteins blood, RNA, Viral blood, Ritonavir therapeutic use, Chemokines, CC blood, HIV Infections drug therapy, HIV Infections immunology, HIV Protease Inhibitors therapeutic use, Interferon-gamma blood, Interleukin-2 blood
Abstract

Cytokines and beta-chemokines play an important role in the complex interaction between HIV-1 and the immune system. We studied platelet-free plasma (PFP) levels and ex vivo production of cytokines and beta-chemokines at different HIV disease stages and the influence of potent protease inhibitor therapy on their production in late-stage patients. Mitogen-induced production of MIP-1alpha, MIP-1beta, and RANTES by PBMCs was higher in HIV-infected patients than in HIV-seronegative controls. Patients with late-stage HIV infection (CD4+ cells <50/microl) showed a higher production of MIP-1alpha and RANTES and lower plasma levels of IL-2 compared with HIV-positive patients at the intermediate stage (CD4+ cells >150/microl). Pretreatment RANTES production correlated negatively with CD4+ and CD8+ cell counts; also, MIP-1alpha production was inversely correlated with CD4+ cell counts. Among patients with a CD4+ cell count <50/microl, RANTES production before protease inhibitor treatment was inversely correlated with viral load. Late-stage patients with IL-2 production higher than 50 pg/ml before treatment showed a more impressive increase in CD4+ cell counts after protease inhibitor therapy. The production of MIP-1alpha, MIP-1beta, RANTES, and IFN-gamma was markedly reduced at 8 weeks and partially restored at 24 weeks after beginning protease inhibitor therapy. PFP levels of RANTES showed a concurrent decrease. Patients with more advanced HIV infection show a higher production of inflammatory cytokines, which is reduced by protease inhibitor therapy. Residual late-stage IL-2 producers may represent a subset of patients with a higher potential for immunologic reconstitution.

Published
2000
Full Text
View/download PDF

31. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy.

Author

De Luca A, Giancola ML, Cingolani A, Ammassari A, Gillini L, Murri R, and Antinori A

Subjects
AIDS-Related Opportunistic Infections mortality, Adult, Anti-HIV Agents therapeutic use, Antiviral Agents administration & dosage, Cytarabine administration & dosage, DNA, Viral cerebrospinal fluid, Drug Therapy, Combination, Female, Humans, Injections, Spinal, JC Virus isolation & purification, Leukoencephalopathy, Progressive Multifocal mortality, Male, Treatment Outcome, AIDS-Related Opportunistic Infections drug therapy, AIDS-Related Opportunistic Infections virology, Antiviral Agents therapeutic use, Cytarabine therapeutic use, Leukoencephalopathy, Progressive Multifocal drug therapy, Leukoencephalopathy, Progressive Multifocal virology
Abstract

We describe the clinical and virological outcome of human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy (PML) treated with cytarabine. Twenty-seven patients received intrathecal cytarabine, 5 received concomitant intravenous cytarabine, and 20 received concomitant antiretroviral therapy. The median baseline CD4+ cell count was 28/mm3. After 4 weeks, 4 (19%) of 21 evaluable patients had stable disease, whereas the others progressed. The median survival from diagnosis and from onset was 66 and 128 days, respectively. Patients with Karnofsky scores of >50 and those previously taking antiretroviral medications had a higher probability of survival 3 months after diagnosis (P = .003 and P = .05, respectively). Overall, after 4 weeks, median JC virus load in CSF increased by 0.7 log10 copies/mL from baseline (P = NS). The mean JC virus load at 4 weeks was lower in patients with stable disease than in progressors (3.47 vs. 4.47 log10 copies/mL; P = .027). JC virus became undetectable in the only patient who had a long-term stable condition. The concentration of JC virus in CSF showed a correlation with clinical outcome.

Published
1999
Full Text
View/download PDF

32. Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy.

Author

De Luca A, Ammassari A, Cingolani A, Giancola ML, and Antinori A

Subjects
Antiviral Agents therapeutic use, Cytarabine therapeutic use, Drug Therapy, Combination, Humans, Treatment Outcome, AIDS-Related Opportunistic Infections drug therapy, Anti-HIV Agents therapeutic use, HIV Protease Inhibitors therapeutic use, Leukoencephalopathy, Progressive Multifocal drug therapy, Reverse Transcriptase Inhibitors therapeutic use
Published
1998

33. Detection of T.gondii-DNA by PCR in AIDS-related toxoplasmic encephalitis.

Author

Cingolani A, De Luca A, Ammassari A, Murri R, Linzalone A, Grillo R, Giancola ML, and Antinori A

Subjects
AIDS-Related Opportunistic Infections cerebrospinal fluid, Animals, Encephalitis cerebrospinal fluid, Humans, Prospective Studies, Toxoplasmosis cerebrospinal fluid, AIDS-Related Opportunistic Infections parasitology, DNA, Protozoan cerebrospinal fluid, Encephalitis parasitology, Polymerase Chain Reaction, Toxoplasma genetics, Toxoplasma isolation & purification, Toxoplasmosis parasitology
Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results